Health Care & Life Sciences » Pharmaceuticals | OncoVista Innovative Therapies Inc.

OncoVista Innovative Therapies Inc. | Balance Sheet

Fiscal year is January-December. All values USD Thousands.
2010
2011
2012
2013
2014
Cash & Short Term Investments
3,524.50
2,125.20
511.70
44.90
12.50
Total Accounts Receivable
7.40
0.40
-
-
-
Other Current Assets
-
52.70
60.10
50.90
-
Total Current Assets
3,531.90
2,178.40
571.80
95.80
12.50
Net Property, Plant & Equipment
16.20
10.20
3.50
0.50
-
Total Investments and Advances
2.00
-
-
-
-
Total Assets
3,550.20
2,188.60
575.30
96.30
12.50
ST Debt & Current Portion LT Debt
100.00
167.70
-
-
200.00
Accounts Payable
506.70
818.50
933.50
-
-
Other Current Liabilities
1,287.10
1,326.40
1,321.00
3,216.10
4,775.70
Total Current Liabilities
1,893.80
2,312.60
2,254.50
3,216.10
4,975.70
Other Liabilities
-
-
-
-
700.00
Total Liabilities
1,893.80
2,312.60
2,254.50
3,216.10
5,675.70
Common Equity (Total)
1,656.30
124.00
1,679.20
3,119.80
5,663.20
Total Shareholders' Equity
1,656.30
124.00
1,679.20
3,119.80
5,663.20
Total Equity
1,656.30
124.00
1,679.20
3,119.80
5,663.20
Liabilities & Shareholders' Equity
3,550.20
2,188.60
575.30
96.30
12.50

About OncoVista Innovative Therapies

View Profile
Address
14785 Omicron Drive
San Antonio Texas 78245
United States
Employees -
Website -
Updated 07/08/2019
OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company produces drug discovery, registration strategies, and emerging technologies. Its products include Cordycepin and L-Nucleoside Conjugate.